Business Wire

MA-CYTOTRONICS

10.7.2024 08:01:25 CEST | Business Wire | Press release

Share
CytoTronics Breaks Scalability Barriers for Monitoring Live Cell Function, Reveals Pixel Octo for High-Throughput Cell Biology Discovery Applications

CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, introduced its high-throughput Pixel™ Octo system at the International Society for Stem Cell Research (ISSCR 2024) in Hamburg, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709748131/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

CytoTronics is launching its high-throughput Pixel™ Octo system (right) at the International Society for Stem Cell Research (ISSCR 2024) in Hamburg, Germany. The ISSCR conference also marks the European reveal of CytoTronics’ product portfolio, including the entry-level Pixel Primo (left), a single plate reader that brings accessibility to researchers. (Photo: Business Wire)

This new addition to the Pixel lineup integrates the company’s semiconductor-to-live-cell interface in an environmental controlled benchtop system to deliver live cell measurements for up to eight 96-well Pixel plates simultaneously. When paired with laboratory robotic automation, the Pixel Octo offers full scalability in high-throughput cell biology applications. The ISSCR conference also marks the European reveal of CytoTronics’ product portfolio, including the entry-level Pixel Primo, a single plate reader that brings accessibility to researchers for under US$30,000.

Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, and more while generating electrical ‘images’ with single-cell spatial resolution. It dramatically accelerates the scale at which cell biology applications can be executed, and the breadth and depth of live-cell insights obtained. Pixel enables new applications for endothelial and epithelial cells, cancer cell biology, mechanism of action/toxicology, stem cell biology, cardiac function, and neural function.

Scale up of in vitro cell-based assays is challenging. Traditionally, these screening assays at high scale use hundreds of 96- or 384- well plates to measure simple cellular properties (e.g., "live or dead" screens) to select the most prospective 'hits' of interest, which are then 'scaled down' to verify key effects on cellular functions. Pixel gives researchers a highly sophisticated tool to start key investigations first, get the functional phenotypic assets they cannot get through imaging and other basic techniques, and easily scale these newly developed assays to high-throughput workflows.

The Pixel plate, a proprietary 96-well electronic microplate embedded with custom-designed semiconductor microchips at the base of each well, is at the core of CytoTronics’ Pixel platform. Cells grow in culture media on top of a microarray containing over 100,000 nanoscale electrode-based sensors, enabling thousands of measurements to be taken per well on a single-cell level, on any cell type, spheroid, or 3D organoid system.

In-vitro cell-based assays can initially be developed on Pixel Primo, a single plate reader that can be placed in any standard cell culture incubator. Cell biologists can then scale those assays 8× on Pixel Octo, a self-contained benchtop system complete with a dedicated incubator to regulate temperature, CO2, humidity, and oxygen. Labs can integrate Pixel Octo with industry standard robotic and liquid handling platforms, and multiple systems can be run in parallel for high-throughput applications. Availability of 384-well Pixel plates later in 2024 raises the scalability bar significantly, adding capability to screen tens of thousands of wells simultaneously.

“There’s a tremendous unmet need in cell biology discovery applications to measure the unique cell parameters that Pixel captures. It unlocks new applications and reveals data that scientists haven’t been able to study before,” said Jeffrey Abbott, Ph.D., Co-Founder and CEO of CytoTronics. “Pixel Octo takes the power of our unique semiconductor-to-biology interface from assay development in a single plate and unleashes it for high-throughput applications, from exploratory assays on a single Pixel plate to fully validated cell-based applications running at industrial scale.”

“Our early access program for the Pixel Primo kicked off in February and already has 20 global partners spanning biotech, pharmaceutical, academic, cell and organoid providers, and computational biology organizations who are very quickly gaining traction on their applications,” said Duane Sword, Co-Founder and CBO at CytoTronics. “Pixel Octo was designed with scalability in mind and provides cell monitoring and data collection at unprecedented scale. Importantly, Pixel is complementary with imaging and HCS (high content screening) techniques and designed to integrate with standard automation workflows. Pixel is rich with information on biology never seen before, let alone at scale. Hence, we have designed the system with a cloud-centric architecture spanning measurement design, execution, analysis and reporting.”

Through the CytoTronics early access program, customers receive a Pixel Primo, 96-well Pixel plates and Pixel Pro, a cloud-based control and interactive analysis software. A starting list price of under $30K (USD) makes it easy for labs to evaluate Pixel as the next frontier of their cell biology research programs.

To learn more about Pixel or enroll in the early access program, visit www.cytotronics.com. You can also visit CytoTronics at ISSCR in Hall H booth #1016 and attend our talks on “Electrical imaging: live cell characterization from stem cell biology to phenotypic disease models”, presented by Shalaka Chitale, CytoTronics’ Director of Biology, Thursday July 11 at 9:10am - 9:20am and Friday July 12 at 6:00pm – 6:30pm.

About Pixel

CytoTronics’ breakthrough semiconductor-to-live-cell interface powered by microchips enables thousands of multi-modal readouts on any cell type or organoid system. Live cell function is monitored on a Pixel plate, a proprietary 96- or 384-well microplate embedded with microchips at the base of each well. Cells grow in culture media on top of a microarray containing over 100,000 nanoscale electrode-based sensors, allowing thousands of measurements to be taken per well. Pixel Primo and Octo offer simultaneous monitoring of cells across all wells of either a single Pixel plate or eight at the same time. Cloud-based Pixel Pro software enables applications across multiple cell types and organoids with cloud-based control and interactive analysis of the data-rich, live cell measurements collected.

About CytoTronics

At CytoTronics, we are transforming cell biology discovery with our high-throughput, semiconductor-based platforms. Our Pixel systems provide live cell insights with single-cell resolution across all cell types. By seamlessly integrating semiconductors with conventional microplates, Pixel unlocks multi-modal electrical, electrochemical, and electrophysiological capabilities, delivering an unprecedented scope of data collection and scale-up for cell biology research, drug development, and pharmaceutical manufacturing applications. Established as a spin-off from Harvard University in 2021, we are headquartered in Boston, Massachusetts. Learn more at www.cytotronics.com or follow us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709748131/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SGCA Honours Communication Excellence Across Asia, Europe and the Arab World3.11.2026 16:52:00 CET | Press release

His Highness Sheikh Dr Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, honoured winners of the 13th Sharjah Government Communication Award (SGCA), organised by the Sharjah Government Media Bureau (SGMB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103972039/en/ SGCA honours communication excellence across Asia, Europe and the Arab world (Photo: AETOSWire) Winners represented China, India, Thailand, Ukraine and the Arab world. Some 433 entries from 31 countries across four continents passed initial screening. The award covered 23 categories across five sectors, including six partner awards. His Excellency Tariq Saeed Allay, Director General of SGMB, highlighted the award’s growth under the vision of His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, noting that it had attracted more than 9,500 entries over five year

BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week3.11.2026 16:03:00 CET | Press release

Company to highlight granted patent portfolio, preclinical semaglutide data and potential applications across future peptide medicines at LSX Investival BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio. BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications. BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inv

Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan3.11.2026 16:00:00 CET | Press release

Five-year agreement builds on Sceye’s successful stratospheric connectivity tests in Japan and advances full-scale deployment of HAPS as stratospheric infrastructure and a key pillar of SoftBank’s strategy for a Ubiquitous Network Sceye, a U.S. aerospace and material science company building High Altitude Platform Systems (HAPS) for stratospheric infrastructure, today announced a five-year Master Services Agreement (MSA) with SoftBank Corp. (TOKYO:9434, “SoftBank”) to manufacture, launch, and operate a fleet of Sceye’s HAPS over Japan with the aim of achieving nationwide coverage. This agreement advances the companies’ partnership from flight demonstrations toward full-scale stratospheric infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103391128/en/ Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan Sceye’s HAPS will form a key pillar of SoftB

Organigram to Acquire Aurora andEstablish a Global Cannabis Leader3.11.2026 15:16:00 CET | Press release

Organigram to acquire Aurora for C$7.80 per Aurora Common Share; Aurora shareholders will have the option to receive such Consideration in cash, Organigram shares or a combination of both, subject to proration. Transaction provides Aurora shareholders with certainty of value, meaningful immediate liquidity and participation in the combined entity Offer represents a 93% premium to Aurora’s Unaffected Share Price on August 10, 20261 and a 21% premium to the implied value of the unsolicited Curaleaf Hostile Bid as of November 2, 20262, unanimously rejected by Aurora’s Board of Directors Organigram shareholders to participate alongside Aurora shareholders in a company with greater scale, enhanced supply chain certainty, global footprint and diversification The combined company will own and operate five EU-GMP certified production and distribution facilities and bring world-class innovation to existing and new markets to meet international demand and support global market share expansion Th

Individual AI Productivity Soars but Organizational Impact Stalls3.11.2026 15:00:00 CET | Press release

Company-wide gains blocked by tool fragmentation and governance gaps; while workers continue to feel the strain of single-player AI and negative impact on wellbeing Miro®, the collaboration and context layer for the AI era, today released research exploring how AI is changing individual productivity and team performance. The survey of over 9,500 leaders and workers finds that while 83% of people believe that AI has improved their individual productivity at work, only 56% say that the quality of output has improved as a result of AI deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103271772/en/ Knowledge workers are individually more capable than ever with the majority now well beyond the ‘foundational stage’ of AI understanding and deployment - according to the Miro report‘The State of Intelligent Collaboration’. But enterprise fragmentation caused by operational silos, misalignment, and AI governance challenges

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye